ORCID Profile
0000-0003-1813-1853
Current Organisations
Seeburg Castle University
,
WU Vienna University of Economicy and Business
,
WU Vienna University of Economics and Business
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Wiley
Date: 09-2009
Publisher: Elsevier BV
Date: 02-2014
Publisher: Georg Thieme Verlag KG
Date: 30-05-2020
Abstract: Coronavirus disease 2019 (COVID-19), currently a worldwide pandemic, is a viral illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The suspected contribution of thrombotic events to morbidity and mortality in COVID-19 patients has prompted a search for novel potential options for preventing COVID-19-associated thrombotic disease. In this article by the Global COVID-19 Thrombosis Collaborative Group, we describe novel dosing approaches for commonly used antithrombotic agents (especially heparin-based regimens) and the potential use of less widely used antithrombotic drugs in the absence of confirmed thrombosis. Although these therapies may have direct antithrombotic effects, other mechanisms of action, including anti-inflammatory or antiviral effects, have been postulated. Based on survey results from this group of authors, we suggest research priorities for specific agents and subgroups of patients with COVID-19. Further, we review other agents, including immunomodulators, that may have antithrombotic properties. It is our hope that the present document will encourage and stimulate future prospective studies and randomized trials to study the safety, efficacy, and optimal use of these agents for prevention or management of thrombosis in COVID-19.
Publisher: Springer Fachmedien Wiesbaden
Date: 2018
Publisher: Nomos
Date: 2009
Publisher: Springer Berlin Heidelberg
Date: 2017
Publisher: Georg Thieme Verlag KG
Date: 28-09-2019
Abstract: Platelet transfusion is conventionally used to prevent or treat bleeding in patients with low platelet counts or impaired platelet function. The identification of accurate thresholds of platelet count for guiding platelet transfusion practices is a crucial aspect in health care to prevent adverse events, side effects, unwarranted costs for the health care service, and deprivation of supplies. This article is therefore aimed at providing a narrative overview on current guidelines and recommendations for platelet transfusion across many clinical settings, including platelet function disorders, and critically analyzing the available platelet transfusion thresholds according to the current analytical performance of platelet counting with automated hematological analyzers. Overall, universal agreement on the definition of platelet transfusion thresholds has not been reached. The degree of accuracy and imprecision of many fully automated hematological analyzers appears also unsatisfactory, especially at the lower thrombocytopenic range, and this may thus jeopardize the managed care of patients who are candidates for platelet transfusions. Potential solutions to overcome the current shortcomings of automated platelet counting are also discussed, encompassing the use of alternative tests for guiding platelet transfusion (e.g., thrombin generation assays or thromboelastography) along with innovative approaches for platelet enumeration (e.g., fluorescent labeling and flow cytometry).
Publisher: Elsevier BV
Date: 04-2016
Publisher: Edward Elgar Publishing
Date: 26-06-2015
Publisher: Routledge
Date: 17-04-2015
Publisher: Emerald
Date: 30-12-2011
Start Date: 2009
End Date: 2013
Funder: Austrian Science Fund
View Funded ActivityStart Date: 2009
End Date: 2011
Funder: Seventh Framework Programme
View Funded ActivityStart Date: 2019
End Date: 2020
Funder: Österreichische Forschungsförderungsgesellschaft
View Funded Activity